BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, February 3, 2026

Urology

Home » Topics » Disease categories and therapies » Urology
  • 10 28 boston science global headquarters marlborough mass
    Jan. 13, 2026
    By Annette Boyle

    Boston Sci’s Valencia buy adds ITNS to urology

    Boston Scientific Corp. plans to acquire Valencia Technologies Corp. in the first half of 2026 in a move that will expand its urology portfolio. Valencia makes the Ecoin system, an implantable tibial nerve stimulator (ITNS) designed to treat urge urinary incontinence (UUI). The companies did not disclose terms of the deal, which is not expected to have a material impact on 2026 earnings per share.
  • Shenzhen edge medical co. ltd. multi port endoscopic surgical robot 12 31
    Dec. 31, 2025
    By Tamra Sami

    Surgical robotic maker Shenzhen Edge announces $154M HKEX IPO

    Surgical robotics maker Shenzhen Edge Medical Co. Ltd. reported its initial public offering on the Hong Kong Stock Exchange to raise HKD$1.19 billion (US$154 million) to advance its pipeline of surgical robotic systems and expand its geographic footprint to markets outside China.
  • Research collaboration deal handshake gloves
    Dec. 17, 2025
    By Shani Alexander

    Siemens, Alzpath sign deal on Alzheimer's diagnostic blood test

    Siemens Healthineers AG became the latest company to sign a licensing agreement with Alzpath Inc. to use its pTau217 antibody in the development of a blood-based diagnostic assay for Alzheimer's disease. Alzpath previously signed deals with the likes of Roche AG and Beckman Coulter Diagnostics Inc. to use its pTau217 antibody to create diagnostic tests based for early detection and monitoring of Alzheimer's.
Read More

Authors

  • Meg Bryant
  • Liz Hollis
  • Stacy Lawrence
  • Bernard Banga
  • Annette Boyle
  • Mark McCarty
More Authors
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing